Association of perfluoroalkyl and polyfluoroalkyl substances with premature ovarian insufficiency in Chinese women

Association of perfluoroalkyl and polyfluoroalkyl substances with premature ovarian insufficiency... Abstract Context Perfluoroalkyl and polyfluoroalkyl substances (PFASs), a group of ubiquitous environmental chemicals with properties of endocrine disruption, are often detectable in humans. Objective The present study investigated the association between exposure to PFAS and primary ovarian insufficiency (POI). Design, Patients, Interventions and Main Outcome Measures Levels of plasma PFAS were measured in 120 Chinese women with overt POI and 120 healthy controls (2013-2016). Associations between PFAS levels and odds of POI, and hormonal profiles were evaluated using multiple logistic regression and multiple linear regression models. Results Levels of perfluorooctanate (PFOA), perfluorooctane sulfonate (PFOS), and perfluorohexanesulfonate (PFHxS) were positively associated with the risks of POI [highest vs. lowest tertile, PFOA: OR = 3.80 (95% CI: 1.92, 7.49); PFOS: 2.81 (95% CI: 1.46, 5.41); PFHxS: 6.63 (95% CI: 3.22, 13.65)]. In POI patients, levels of PFOS and PFHxS exposure were positively associated with follicle-stimulating hormone [PFOS: adjusted β = 0.26 (95% CI: 0.15, 0.38); PFHxS: 0.16 (95% CI: 0.04, 0.28)] and negatively associated with estradiol [PFOS: -0.30 (95% CI: -0.47, -0.12); PFHxS: -0.19 (95% CI: -0.37, -0.02)]. In addition, the exposure to PFOS and PFOA were associated with elevation of prolactin [PFOS: 0.17 (95% CI: 0.06, 0.29); PFOA: 0.16 (95% CI: 0.01, 0.30)] or decrease of free triiodothyronine [PFOS: -0.88 (95% CI: -1.64, -0.09); PFOA: -0.90 (95% CI: -1.88, 0.09)] and thyroxine [PFOS: -2.99 (95% CI: -4.52, -1.46); PFOA: -3.42 (95% CI: -5.39, -1.46)]. Conclusion High exposure to PFOA, PFOS, and PFHxS is associated with increased risk of POI in human. Clinical trial registration number: 2013-MD-062 Copyright © 2018 Endocrine Society http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Endocrinology and Metabolism Oxford University Press

Association of perfluoroalkyl and polyfluoroalkyl substances with premature ovarian insufficiency in Chinese women

Loading next page...
 
/lp/ou_press/association-of-perfluoroalkyl-and-polyfluoroalkyl-substances-with-RYIA7KCbaY
Publisher
Endocrine Society
Copyright
Copyright © 2018 Endocrine Society
ISSN
0021-972X
eISSN
1945-7197
D.O.I.
10.1210/jc.2017-02783
Publisher site
See Article on Publisher Site

Abstract

Abstract Context Perfluoroalkyl and polyfluoroalkyl substances (PFASs), a group of ubiquitous environmental chemicals with properties of endocrine disruption, are often detectable in humans. Objective The present study investigated the association between exposure to PFAS and primary ovarian insufficiency (POI). Design, Patients, Interventions and Main Outcome Measures Levels of plasma PFAS were measured in 120 Chinese women with overt POI and 120 healthy controls (2013-2016). Associations between PFAS levels and odds of POI, and hormonal profiles were evaluated using multiple logistic regression and multiple linear regression models. Results Levels of perfluorooctanate (PFOA), perfluorooctane sulfonate (PFOS), and perfluorohexanesulfonate (PFHxS) were positively associated with the risks of POI [highest vs. lowest tertile, PFOA: OR = 3.80 (95% CI: 1.92, 7.49); PFOS: 2.81 (95% CI: 1.46, 5.41); PFHxS: 6.63 (95% CI: 3.22, 13.65)]. In POI patients, levels of PFOS and PFHxS exposure were positively associated with follicle-stimulating hormone [PFOS: adjusted β = 0.26 (95% CI: 0.15, 0.38); PFHxS: 0.16 (95% CI: 0.04, 0.28)] and negatively associated with estradiol [PFOS: -0.30 (95% CI: -0.47, -0.12); PFHxS: -0.19 (95% CI: -0.37, -0.02)]. In addition, the exposure to PFOS and PFOA were associated with elevation of prolactin [PFOS: 0.17 (95% CI: 0.06, 0.29); PFOA: 0.16 (95% CI: 0.01, 0.30)] or decrease of free triiodothyronine [PFOS: -0.88 (95% CI: -1.64, -0.09); PFOA: -0.90 (95% CI: -1.88, 0.09)] and thyroxine [PFOS: -2.99 (95% CI: -4.52, -1.46); PFOA: -3.42 (95% CI: -5.39, -1.46)]. Conclusion High exposure to PFOA, PFOS, and PFHxS is associated with increased risk of POI in human. Clinical trial registration number: 2013-MD-062 Copyright © 2018 Endocrine Society

Journal

Journal of Clinical Endocrinology and MetabolismOxford University Press

Published: May 4, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off